Hyphens Pharma International Limited (SGX:1J5)
Singapore · Delayed Price · Currency is SGD 0.3350
-0.0050 (-1.47%)
At close: Jul 31, 2025
SGXC:1J5 Income Statement
Financials in millions SGD. Fiscal year is January - December.
Millions SGD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 195.42 | 170.6 | 162.32 | 125.88 | 120.98 | Upgrade | |
Revenue Growth (YoY) | 14.55% | 5.10% | 28.94% | 4.06% | 1.29% | Upgrade |
Cost of Revenue | 127.18 | 109.57 | 100.04 | 78.47 | 79.39 | Upgrade |
Gross Profit | 68.24 | 61.03 | 62.28 | 47.41 | 41.58 | Upgrade |
Selling, General & Admin | 54.91 | 50.02 | 47.83 | 39.62 | 36.66 | Upgrade |
Operating Expenses | 54.91 | 50.02 | 47.83 | 39.62 | 36.66 | Upgrade |
Operating Income | 13.34 | 11.01 | 14.45 | 7.79 | 4.92 | Upgrade |
Interest Expense | -0.57 | -0.28 | -0.24 | -0.1 | -0.11 | Upgrade |
Interest & Investment Income | 0.15 | 0.34 | 0.04 | 0.07 | 0.18 | Upgrade |
Earnings From Equity Investments | - | 0.55 | 0.47 | 0.02 | - | Upgrade |
Currency Exchange Gain (Loss) | -0.35 | -1.41 | -0.92 | 0.46 | 0.05 | Upgrade |
Other Non Operating Income (Expenses) | 0.44 | 0.19 | 0.49 | 0.43 | 0.3 | Upgrade |
EBT Excluding Unusual Items | 13.02 | 10.4 | 14.29 | 8.68 | 5.34 | Upgrade |
Merger & Restructuring Charges | -0.07 | - | - | -0.42 | - | Upgrade |
Gain (Loss) on Sale of Investments | - | 0.17 | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | 0.01 | 0.01 | -0 | -0 | 0 | Upgrade |
Other Unusual Items | - | - | - | - | 1.77 | Upgrade |
Pretax Income | 12.96 | 10.57 | 14.29 | 8.26 | 7.11 | Upgrade |
Income Tax Expense | 2.1 | 1.99 | 2.88 | 1.41 | 0.95 | Upgrade |
Earnings From Continuing Operations | 10.86 | 8.58 | 11.41 | 6.85 | 6.16 | Upgrade |
Minority Interest in Earnings | -0.66 | -0.01 | -0.06 | - | - | Upgrade |
Net Income | 10.19 | 8.57 | 11.35 | 6.85 | 6.16 | Upgrade |
Net Income to Common | 10.19 | 8.57 | 11.35 | 6.85 | 6.16 | Upgrade |
Net Income Growth | 18.98% | -24.52% | 65.81% | 11.08% | -5.62% | Upgrade |
Shares Outstanding (Basic) | 309 | 309 | 309 | 301 | 300 | Upgrade |
Shares Outstanding (Diluted) | 315 | 309 | 310 | 302 | 300 | Upgrade |
Shares Change (YoY) | 1.74% | -0.27% | 2.66% | 0.60% | 0.05% | Upgrade |
EPS (Basic) | 0.03 | 0.03 | 0.04 | 0.02 | 0.02 | Upgrade |
EPS (Diluted) | 0.03 | 0.03 | 0.04 | 0.02 | 0.02 | Upgrade |
EPS Growth | 16.97% | -24.32% | 61.23% | 10.73% | -5.73% | Upgrade |
Free Cash Flow | -1.12 | 5.34 | 16.32 | 5.34 | 3.76 | Upgrade |
Free Cash Flow Per Share | -0.00 | 0.02 | 0.05 | 0.02 | 0.01 | Upgrade |
Dividend Per Share | 0.015 | 0.009 | 0.011 | 0.007 | 0.006 | Upgrade |
Dividend Growth | 74.42% | -22.52% | 65.67% | 8.06% | -38.00% | Upgrade |
Gross Margin | 34.92% | 35.77% | 38.37% | 37.66% | 34.37% | Upgrade |
Operating Margin | 6.83% | 6.46% | 8.90% | 6.19% | 4.07% | Upgrade |
Profit Margin | 5.22% | 5.02% | 6.99% | 5.44% | 5.09% | Upgrade |
Free Cash Flow Margin | -0.57% | 3.13% | 10.05% | 4.24% | 3.11% | Upgrade |
EBITDA | 14.88 | 12.63 | 16.05 | 9.09 | 6.17 | Upgrade |
EBITDA Margin | 7.61% | 7.40% | 9.89% | 7.22% | 5.10% | Upgrade |
D&A For EBITDA | 1.54 | 1.62 | 1.6 | 1.3 | 1.25 | Upgrade |
EBIT | 13.34 | 11.01 | 14.45 | 7.79 | 4.92 | Upgrade |
EBIT Margin | 6.83% | 6.46% | 8.90% | 6.19% | 4.07% | Upgrade |
Effective Tax Rate | 16.24% | 18.79% | 20.17% | 17.08% | 13.30% | Upgrade |
Advertising Expenses | 9.26 | 8.87 | 8.24 | 8.58 | 8.91 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.